Response to combination antiretroviral therapy: Variation by age

AIDS

Volumn 22, Issue 12, 2008, Pages 1463-1473

  Sabin, Caroline A ^a   Smith, Colette J ^b   D'Arminio Monforte, Antonella ^b   Battegay, Manuel ^b   Gabiano, Clara ^b   Galli, Luisa ^b   Geelen, Sibyl ^b   Gibb, Diana ^b   Guiguet, Marguerite ^b   Judd, Ali ^b   Leport, Catherine ^b   Dabis, François ^b   Pantazis, Nikos ^b   Porter, Kholoud ^b   Raffi, Francois ^b   Thorne, Claire ^b   Torti, Carlo ^b   Walker, Sarah ^b   Warszawski, Josiane ^b   Wintergerst, Uwe ^b   Chene, Genevieve ^b   Lundgren, Jens ^b   Weller, Ian ^b   Costagliola, Dominique ^b   Ledergerber, Bruno ^b   Touloumi, Giota ^b   Meyer, Laurence ^b   Krause, Murielle Mary ^b   Goujard, Cecile ^b   de Wolf, Frank ^b   Reiss, Peter ^b   Dorrucci, Maria ^b   Sabin, Caroline ^b   Del Amo, Julia ^b   Obel, Niels ^b   Mocroft, Amanda ^b   Kirk, Ole ^b   Staszewski, Schlomo ^b   Perez Hoyos, Santiago ^b   Almeda, Jesus ^b   Antinori, Andrea ^b   Tovo, Pier Angelo ^b   Salzberger, Bernd ^b   Fatkenheuer, Gerd ^b   Ramos, Jose ^b   Mussini, Cristina ^b   Tookey, Pat ^b   Casabona, Jordi ^b   Miro, Jose M ^b   Castagna, Antonella ^b   de Wit, Stephane ^b   Teira, Ramon ^b   Garrido, Myriam ^b   Dedes, Nikos ^b   Phillips, Andrew ^b   Furrer, Hansjakob ^b   Egger, Matthias ^b   Newell, Marie Louise ^b   Sterne, Jonathan ^b   Telenti, Amalio ^b   more..

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

Age; Clinical outcome; Combination antiretroviral therapy; HIV infection; Immunological response; Virological response

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; DEATH; FEMALE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STANDARD; SURVIVAL; TREATMENT RESPONSE; AGE; AGE DISTRIBUTION; AGED; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; EUROPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEWBORN; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EUROPE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 49849095857     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f88d02     Document Type: Article

References (41)

1. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-296.
2. Palella FJ, Chmiel JS, Moorman AC, Holmberg SD, and the HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16:1617-1626.
3. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500cells/L in HIV type 1 infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-372.
4. Lampe FC, Smith CJ, Madge S, Kinloch-de-Loes S, Tyrer M, Sabin CA, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167:692-700.
5. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organisation (WHO). AIDS Epidemic update; 2006. http://wwwunaidsorg/en/HIV-data/ epi2006/defaultasp.
6. EuroHIV (European Centre for the Epidemiological Monitoring of AIDS). HIV/AIDS Surveillance in Europe; 2003. Report No. 2003.
7. Le Moing V, Chene G, Carrieri MP, Besnier JM, Masquelier B, Salamon R, et al. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001; 27:372-376.
8. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54:1481-1496.
9. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029-2038.
10. Nogureras M, Navarro G, Anton E, Sala M, Cervantes M, Amengual M, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis 2006; 6: 159.
11. Uphold CR, Maruenda J, Yarandi HN, Sleasman JW, Bender BS. HIV and older adults: clinical outcomes in the era of HAART. J Gerontol Nurs 2004; 30:16-24.
12. Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7:549-557.
13. Tumbarello M, Rabagliati R, de Gaetano Donati K, Bertagnolio S, Montuori E, Tamburrini E, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004; 4:46.
14. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735-746.
15. Bonnet F, Thiebaut R, Chene G, Neau D, Pellegrin JL, Mercie P, et al. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med 2005; 6:198-205.
16. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1 -infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
17. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-Infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-1294.
18. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-434.
19. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years. Arch Intern Med 2003; 163:2187-2195.
20. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-1915.
21. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4:255-262.
22. Marimoutou C, Chene G, Mercie P, Neau D, Farbos S, Morlat P, et al. Prognostic factors of combined viral load and CD4R cell count responses under triple antiretroviral therapy, Aquitaine Cohort, 1996-1998. J Acquir Immune Defic Syndr 2001; 27:161-167.
23. Walker AS, Doerholt K, Sharland M, Gibb DM, Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-1924.
24. De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type-1 infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis 2002; 186:312-320.
25. Kjaer J, Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. Antivir Ther 2004; 9:631-633.
26. Dunn D, HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1 -infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:1605-1611.
27. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of HAART: uptake of and responses to antiretroviral therapy. AIDS 2004; 18:2145-2151.
28. Molina-Pinelo S, Vivancos J, De Felipe B, Soriano-Sarabia N, Valladares A, De la Rosa R, et al. Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption. J Acquir Immune Defic Syndr 2006; 42:203-206.
29. The D:A:D Study. Liver-related deaths in persons infected with the human immunodeficiency virus. Arch Int Med 2006; 166:1632-1641.
30. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
31. d'Arminio Monforte A, Abrams D, Pradier C, Weber R, Bonnet F, de Wit S, et al. HIV-induced immunodeficiency and risk of fatal AIDS-defining and non-AIDS-defining malignancies: results from the D:A:D Study. Abstract 84. Presented at 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles; 25-28 February 2007.
32. Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR, et al. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005; 159:764-770.
33. Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FAI, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006; 332:1183-1187.
34. Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, et al. Outcomes for human immunodeficiency virus-1 -infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J 2006; 25:420-426.
35. Bofill M, Janossy G, Lee CA, Macdonald-Burns D, Phillips AN, Sabin CA, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol 1992; 88:243-252.
36. European Collaborative Study. Age related standards for total lymphocyte, CD4R and CD8R T cell counts in children born in Europe. Pediatr Infect DisJ 2005; 24:595-600.
37. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994; 13:2359-2367.
38. Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral treatment in HIV-infected children and adults. J Infect Dis 2008; 197:398-404.
39. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy. HIV Med 2004; 5 (S2):61-86.
40. European Collaborative Study. Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? AIDS 2003; 16:97-104.
41. Kuyper LM, Wood E, Montaner JSG, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004; 37:1470-1476.